MeSH tree: C15.378.508.539.275
Compared with white patients, Black patients with an aggressive form of leukemia—called acute myeloid leukemia (AML)—were on average more than five years younger at diagnosis and more than 30% more likely to die of their ...
Dec 17, 2025
0
7
Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation. In myelodysplastic syndrome (MDS), however, this ...
Dec 13, 2025
0
19
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.
Dec 9, 2025
0
29
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive ...
Dec 9, 2025
0
12
A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing myelodysplastic syndrome (MDS), tend to develop it earlier, and often have more aggressive disease that is ...
Dec 8, 2025
0
18
A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: It depends on when in development the ...
Dec 8, 2025
0
14
Scientists from Duke-NUS Medical School and their international collaborators have developed a new computational tool that maps how gene pathways interact in complex biological systems. Using this novel algorithm, the team ...
Dec 8, 2025
0
33
In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy. The azacitidine–venetoclax ...
Dec 8, 2025
0
11
Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more than 20% more likely to ...
Dec 8, 2025
0
7
Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable residual disease (MRD), may provide an early and reliable indicator of long-term outcomes for patients ...
Dec 8, 2025
0
8
